Prognostic value of preoperative absolute lymphocyte count in recurrent hepatocellular carcinoma following thermal ablation: A retrospective analysis

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1829-1835

  Li, Xin ^a   Han, Zhiyu ^a   Cheng, Zhigang ^a   Yu, Jie ^a   Yu, Xiaoling ^a   Liang, Ping ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Absolute lymphocyte count; Recurrence; Recurrent hepatocellular carcinoma; Thermal ablation

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; THERMAL ABLATION; TUMOR ABLATION; TUMOR DIFFERENTIATION; TUMOR VOLUME; VERY ELDERLY;

EID: 84908157901     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S69227     Document Type: Article

References (23)

1. Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047-2063.
4. Faber W, Stockmann M, Schirmer C, et al. Significant impact of patient age on outcome after liver resection for HCC in cirrhosis. Eur J Surg Oncol. 2014;40:208-213.
5. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-773.
6. Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford). 2007;9:429-434.
7. Liang P, Yu J, Yu XL, et al. Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: a multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China. Gut. 2012;61:1100-1101.
8. O'Keefe SJ, El-Zayadi AR, Carraher TE, Davis M, Williams R. Malnutrition and immuno-incompetence in patients with liver disease. Lancet. 1980;2:615-617.
9. Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation. Transplantation. 2014;97:694-701.
10. Milne K, Alexander C, Webb JR, et al. Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 2012;10:33.
11. Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970;25:135-140.
12. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383-5391.
13. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology. 2012;1:48-55.
14. Zhou P, Liang P, Yu X, Wang Y, Dong B. Percutaneous microwave ablation of liver cancer adjacent to the gastrointestinal tract. J Gastrointest Surg. 2009;13:318-324.
15. Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation - complications among cohort of 1136 patients. Radiology. 2009;251:933-940.
16. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344.
17. Ströhlein MA, Lefering R, Bulian DR, Heiss MM. Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy. Med Hypotheses. 2014;82:295-299.
18. Watanabe R, Tomita N, Itabashi M, et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol. 2014;92:204-210.
19. Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer. 2014;85: 101-109.
20. Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal cancer immunotherapy. Discov Med. 2013;15:301-308.
21. Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol. 2014;20:1657-1666.
22. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39:11-26.
23. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.